BIOGEN INC (BIIB)
US09062X1037 - Common Stock
BIIB gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. BIIB has an excellent profitability rating, but there are some minor concerns on its financial health. BIIB has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
BIIB had a positive operating cash flow in the past year.
In the past 5 years BIIB has always been profitable.
Each year in the past 5 years BIIB had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.33%, BIIB belongs to the top of the industry, outperforming 96.06% of the companies in the same industry.
BIIB has a Return On Equity of 7.85%. This is amongst the best in the industry. BIIB outperforms 95.72% of its industry peers.
The Return On Invested Capital of BIIB (7.53%) is better than 96.23% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIIB is in line with the industry average of 13.58%.
The 3 year average ROIC (11.97%) for BIIB is well above the current ROIC(7.53%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.33% | ||
| ROE | 7.85% | ||
| ROIC | 7.53% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)11.97%
ROIC(5y)17.09%
1.3 Margins
Looking at the Profit Margin, with a value of 11.81%, BIIB belongs to the top of the industry, outperforming 96.40% of the companies in the same industry.
BIIB's Profit Margin has declined in the last couple of years.
BIIB's Operating Margin of 20.84% is amongst the best of the industry. BIIB outperforms 96.92% of its industry peers.
In the last couple of years the Operating Margin of BIIB has declined.
The Gross Margin of BIIB (74.24%) is better than 85.45% of its industry peers.
BIIB's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.84% | ||
| PM (TTM) | 11.81% | ||
| GM | 74.24% |
OM growth 3Y-17.42%
OM growth 5Y-15.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.99%
GM growth 5Y-3.01%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
The number of shares outstanding for BIIB has been increased compared to 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
Compared to 1 year ago, BIIB has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.09 indicates that BIIB is not in any danger for bankruptcy at the moment.
The Altman-Z score of BIIB (3.09) is better than 75.68% of its industry peers.
The Debt to FCF ratio of BIIB is 5.61, which is a neutral value as it means it would take BIIB, 5.61 years of fcf income to pay off all of its debts.
BIIB has a Debt to FCF ratio of 5.61. This is amongst the best in the industry. BIIB outperforms 94.86% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that BIIB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.46, BIIB is not doing good in the industry: 72.09% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.61 | ||
| Altman-Z | 3.09 |
ROIC/WACC0.93
WACC8.12%
2.3 Liquidity
A Current Ratio of 2.00 indicates that BIIB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 2.00, BIIB is doing worse than 77.40% of the companies in the same industry.
A Quick Ratio of 1.26 indicates that BIIB should not have too much problems paying its short term obligations.
BIIB's Quick ratio of 1.26 is on the low side compared to the rest of the industry. BIIB is outperformed by 84.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
BIIB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.27%.
The earnings per share for BIIB have been decreasing by -10.49% on average. This is quite bad
BIIB shows a decrease in Revenue. In the last year, the revenue decreased by -3.32%.
The Revenue has been decreasing by -6.07% on average over the past years.
EPS 1Y (TTM)-18.27%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS growth Q2Q-18.52%
Revenue 1Y (TTM)-3.32%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Revenue growth Q2Q-6.2%
3.2 Future
The Earnings Per Share is expected to grow by 9.22% on average over the next years. This is quite good.
BIIB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.13% yearly.
EPS Next Y4.52%
EPS Next 2Y9.2%
EPS Next 3Y10.42%
EPS Next 5Y9.22%
Revenue Next Year-4.77%
Revenue Next 2Y-1.75%
Revenue Next 3Y0.57%
Revenue Next 5Y2.13%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 12.81, BIIB is valued correctly.
Based on the Price/Earnings ratio, BIIB is valued cheaply inside the industry as 98.12% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.20. BIIB is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 12.26, the valuation of BIIB can be described as correct.
98.12% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.60. BIIB is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.81 | ||
| Fwd PE | 12.26 |
4.2 Price Multiples
96.92% of the companies in the same industry are more expensive than BIIB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 96.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.72 | ||
| EV/EBITDA | 13.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIIB does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of BIIB may justify a higher PE ratio.
PEG (NY)2.84
PEG (5Y)N/A
EPS Next 2Y9.2%
EPS Next 3Y10.42%
5. Dividend
5.1 Amount
No dividends for BIIB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOGEN INC
NASDAQ:BIIB (4/23/2024, 7:00:01 PM)
After market: 193.45 +0.27 (+0.14%)193.18
-0.93 (-0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap28.08B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.81 | ||
| Fwd PE | 12.26 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)2.84
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.33% | ||
| ROE | 7.85% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 20.84% | ||
| PM (TTM) | 11.81% | ||
| GM | 74.24% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-18.27%
EPS 3Y-22.83%
EPS 5Y
EPS growth Q2Q
EPS Next Y4.52%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.32%
Revenue growth 3Y-9.9%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y